Can a pill succeed where Alzheimer’s drugs struggle?

Oligomerix secures $1.9 million in NIH funding to advance an oral Alzheimer’s therapy targeting tau protein. Goodbye, infusion centers? Approved Alzheimer’s blockbusters like Leqembi and Kisunla require regular intravenous infusions or injections at specialized clinics. For many patients and families, treatment means scheduling appointments, arranging transportation, taking time off work and navigating a healthcare system […] The post Can a pill succeed where Alzheimer’s drugs struggle? appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.